Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Xenon PharmaceuticalsXENE | Open-market buy | 09/30 | 10/01 | 15,000 sh | $37.32 | $559,740 | No record | |
Ian MortimerPresident & CEO | Xenon PharmaceuticalsXENE | Open-market buy | 09/30 | 10/01 | 30,000 sh | $37.38 | $1,121,400 | +150.6% |
Gary PatouDirector | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 06/05 | 06/08 | 1,322 sh | $53.14 | $70,251.08 | −5.0% |
Gillian CannonDirector | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 06/05 | 06/08 | 1,190 sh | $53.14 | $63,236.6 | −45.0% |
Ian MortimerPresident & CEO | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/13 | 03/13 | 7,308 sh | $55.23 | $403,620.84 | −26.8% |
Andrea DiFabioChief Legal Officer | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/13 | 03/13 | 1,342 sh | $55.23 | $74,118.66 | −15.5% |
Christopher John KenneyChief Medical Officer | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/13 | 03/13 | 1,410 sh | $55.23 | $77,874.3 | −16.6% |
Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/09–03/10 | 03/11 | 281,269 sh10 trades | $60.32avg. | $16,966,522.09 | −95.0% | |
Andrea DiFabioChief Legal Officer | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/10 | 03/11 | 2,607 sh | $60.11 | $156,706.77 | −34.8% |
Christopher John KenneyChief Medical Officer | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 03/10 | 03/11 | 2,771 sh | $60.11 | $166,564.81 | −36.9% |
Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 01/02 | 01/02 | 40,000 sh2 trades | $44.43avg. | $1,777,092.86 | −87.0% | |
Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 25/12/05–25/12/08 | 25/12/09 | 25,205 sh3 trades | $45.33avg. | $1,142,513.25 | −80.8% | |
Ian MortimerPresident & CEO | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 25/11/28 | 25/12/03 | 97 sh | $45.01 | $4,365.97 | −0.3% |
Ian MortimerPresident, CEO & Interim CFO | Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 25/10/01 | 25/10/01 | 25,000 sh | $40.16 | $1,004,000 | −44.4% |
Steven GannonDirector | Xenon PharmaceuticalsXENE | Open-market sale | 25/06/05 | 25/06/06 | 3 sh | $30.48 | $91.44 | −0.0% |
Xenon PharmaceuticalsXENE | Open-market sale10b5-1 plan | 25/01/23–25/01/27 | 25/01/27 | 55,000 sh4 trades | $40.25avg. | $2,213,996.75 | −63.7% | |
Xenon PharmaceuticalsXENE | Open-market sale | 24/12/18 | 24/12/19 | 18,709 sh2 trades | $41.21avg. | $770,911.67 | −100.0% | |
Xenon PharmaceuticalsXENE | Open-market sale | 24/11/22 | 24/11/22 | 4,891 sh2 trades | $41.08avg. | $200,946.61 | −17.2% | |
Garofalo Elizabeth A.Director | Xenon PharmaceuticalsXENE | Open-market sale | 24/03/08 | 24/03/11 | 2,092 sh | $45.69 | $95,583.48 | −100.0% |
Xenon PharmaceuticalsXENE | Open-market sale | 24/03/07 | 24/03/08 | 7,137 sh2 trades | $46.28avg. | $330,290.25 | −45.9% |
